17.20
Adma Biologics Inc Borsa (ADMA) Ultime notizie
ADMA Biologics (NASDAQ:ADMA) Is Posting Healthy Earnings, But It Is Not All Good News - 富途牛牛
Why ADMA Biologics Inc. stock attracts strong analyst attentionFree Double Return Watchlist - thegnnews.com
ADMA projects $1.1B revenue before 2030 as yield enhancement drives margin expansion and ASCENIV growth - MSN
How did ADMA's revenue surge in Q4 2024 impact its profitability? - AInvest
ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform - Seeking Alpha
Insider Sellers Might Regret Selling ADMA Biologics Shares at a Lower Price Than Current Market Value - 富途牛牛
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum - MSN
ADMA Biologics Thrives With Blockbuster Growth And New FDA Edge - Finimize
ADMA Biologics' Stock Underperforms After Q1 Results - AInvest
ADMA Biologics: A Better Quarter Than Headline Numbers (NASDAQ:ADMA) - Seeking Alpha
ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2025 Earnings Call Transcript - Insider Monkey
ADMA Biologics 2025 Q2 Earnings Strong Performance as Net Income Rises 6.7% - AInvest
ADMA Biologics Secures $300M Credit Agreement with JPMorgan - AInvest
ADMA Biologics Earnings Call Highlights Robust Growth - TipRanks
ADMA Biologics Rides ASCENIV Demand To Higher Guidance - Finimize
ADMA Biologics Outpaces Expectations With Upbeat Growth Plans - Finimize
Noteworthy Thursday Option Activity: ADMA, SMMT, ICHR - Nasdaq
ADMA Biologics Sees Promising Gains Amid Strategic Shifts and Rising Market Trends - timothysykes.com
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
ADMA Beats On Q2 Earnings And Revenues, Asceniv Drives Momentum - Barchart.com
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: ADMA Biologics Q2 2025 misses earnings expectations - Investing.com
ADMA Biologics Inc earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
Adma Biologics (ADMA) Q2 Revenue Up 14% - AOL.com
ADMA Biologics Reports Strong Q2 2025 Results - TipRanks
ADMA Biologics Q2 2025 Earnings Call Transcript - MarketBeat
ADMA Biologics (ADMA) Projects Significant Growth with Yield Process and Refinancing - GuruFocus
ADMA Biologics: A Tale of Two Narratives—Strong Fundamentals vs. a Pessimistic Rating - AInvest
ADMA Biologics' Q2 2025: Unraveling Contradictions in Yield Enhancements, Reimbursement, and Demand Dynamics - AInvest
ADMA Biologics Q2 2025 Earnings Call Transcript Review - AInvest
ADMA Biologics' Q2 2025 Earnings and Strategic Outlook: Navigating Insider Sales and Risk Disclosures for Long-Term Value - AInvest
ADMA Biologics Inc earnings missed, revenue fell short of estimates - Investing.com
Transcript : ADMA Biologics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
Adma Biologics: Q2 Earnings Snapshot - San Antonio Express-News
Adma Biologics Q2 Earnings: Impressive Growth in Net Income and RevenueNews and Statistics - IndexBox
ADMA BIOLOGICS, INC. SEC 10-Q Report - TradingView
Why ADMA Biologics Shares Are Under Pressure - TipRanks
ADMA Biologics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Adma Biologics reports Q2 EPS 14c, consensus 14c - TipRanks
ADMA Biologics Reports Q2 EPS of $0.14, Revenue of $122M Exceeds Expectations - AInvest
ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
ADMA Biologics Reports 14% YoY Revenue Growth and Significant Financial Milestones in 2Q 2025 - Quiver Quantitative
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):